US phase 1 first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors.

CONCLUSIONS: Taletrectinib has manageable toxicities at the MTD of 800 mg daily. Preliminary efficacy was observed in crizotinib-refractory ROS1+ NSCLC patients.
PMID: 32591465 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - June 25, 2020 Category: Cancer & Oncology Authors: Papadopoulos KP, Borazanci E, Shaw AT, Katayama R, Shimizu Y, Zhu VW, Sun TY, Wakelee HA, Madison R, Schrock AB, Senaldi G, Nakao N, Hanzawa H, Masaya T, Isoyama T, Nakamaru K, Deng C, Li M, Fran F, Zhao Q, Gao Y, Seto T, Janne PA, Ou SI Tags: Clin Cancer Res Source Type: research